Diurnal takes commercialization of hydrocortisone portfolio worldwide

Days after announcing it would commercialize its adrenal insufficiency therapy Alkindi (hydrocortisone) in Europe, London-based Diurnal (AIM: DNL) has lined up a commercialization deal in Australia and New Zealand.

Under the terms of the deal, Australia’s Emerge Health will market and sell both Alkindi and Chronocort (hydrocortisone) in the countries, and will submit a regulatory submission there later this year.

The submission will incorporate data from the European regulatory dossier which recently won approval for Alkindi for pediatric use. A decision is expected in 2020.